Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
A new pilot study, published in 2026 in the Journal of Neurodevelopmental Disorders, examined the acute effects of the drug gaboxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, THIP) on brain activity and behavior in adult men with fragile X syndrome, and tested whether EEG recordings made in participants’ homes are reliable. Fragile X syndrome is the most common inherited cause of intellectual disability and is also regarded as one of the most common genetic causes of autism spectrum disorder. It is caused by a mutation in the FMR1 gene on the X chromosome that silences the gene, leaving the body without the protein FMRP. The typical result is cognitive impairment, delayed speech, behavioral difficulties, and sensory hypersensitivity. Despite successful animal studies, the US Food and Drug Administration (FDA) has not yet approved any treatment for the syndrome, which makes the search for biomarkers that carry over from animal models to humans an important line of research.
The study enrolled ten adult men aged 18 to 40 with a confirmed full mutation of the FMR1 gene. In a double-blind crossover design, each participant received a 10 mg dose of gaboxadol twice and a placebo twice, spread across two sessions in the lab and two at home. Before and after each dose, the researchers recorded high-density resting EEG and responses to sound in a chirp paradigm, and ran cognitive tests including the NIH Toolbox and the RBANS word list learning task.
Gaboxadol is a synthetic analog of muscimol, the active compound of the fly agaric mushroom. It acts as a selective agonist that binds specifically to extrasynaptic GABA-A receptors containing delta subunits. In the analysis, a single dose significantly increased theta and alpha activity in the resting EEG. The peak frequency also shifted downward, and the share of slow oscillations increased. However, the gamma abnormalities typical of fragile X syndrome did not normalize, and responses to sound did not change. The cognitive tests showed no significant effect on the NIH Toolbox either, and word list learning showed only a trend in favor of the drug that did not reach statistical significance.
No serious adverse events were recorded. The main side effect was fatigue, reported four times during the lab sessions and twice at home while participants were taking gaboxadol. The sample is too small, however, to allow any reliable judgment of safety or efficacy with longer-term use. One of the study’s main results concerns its method: the data showed no meaningful differences between recordings made at home and in the lab, evidence that decentralized EEG collection is feasible and reliable. This could make future clinical trials easier to run and, in particular, open them to patients for whom regular trips to a research center are difficult.